Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GILDESS 1/20 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (Gn RH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Treatment of moderate acne vulgaris,Contraceptive for women with menstrual disorders
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Ethinylestradiol: terminal half-life ~13-27 hours (mean 17 hours). Gestodene: terminal half-life ~12-15 hours. Steady-state reached within 5-7 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Both ethinyl estradiol and gestodene are metabolized primarily in the liver via the cytochrome P450 3A4 (CYP3A4) pathway. Ethinyl estradiol undergoes first-pass metabolism and enterohepatic recirculation; gestodene is hydroxylated and conjugated.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal (estradiol: ~40-50% as glucuronide and sulfate conjugates; gestodene: ~30-40% as metabolites) and fecal (estradiol: ~20-30%; gestodene: ~30-40%). Less than 1% excreted unchanged.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Ethinylestradiol: 98% bound to albumin. Gestodene: 75-90% bound to sex hormone-binding globulin (SHBG) and albumin.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Ethinylestradiol: ~2.4 L/kg. Gestodene: ~0.7 L/kg. Indicates extensive tissue distribution.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: Ethinylestradiol ~40-60% (first-pass metabolism). Gestodene ~99% (highly bioavailable due to minimal first-pass effect).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dosage adjustment required for mild-to-moderate renal impairment. Insufficient data for severe renal impairment; use with caution.
No data available for fictional drug ALYACEN 777.
Contraindicated in hepatic adenomas, active liver disease, or Child-Pugh class B/C cirrhosis. For mild hepatic impairment (Child-Pugh A), no dosage adjustment; monitor.
No data available for fictional drug ALYACEN 777.
Not indicated for use in pediatric patients before menarche. Post-menarche, same as adult dosing; use only after establishment of regular menstrual cycles.
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenopausal women. No specific geriatric dosing; generally not used in elderly women due to increased risk of thromboembolism.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is particularly pronounced in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Risk of thromboembolic disorders (venous and arterial), including myocardial infarction and stroke,Increased risk of hypertension and associated vascular complications,Potential hepatic neoplasia (benign and malignant),Possible exacerbation of cholestatic jaundice or gallbladder disease,May cause fluid retention, which can aggravate conditions such as migraine, asthma, cardiac, or renal dysfunction,Altered carbohydrate metabolism: monitor glucose in diabetic patients,May worsen depression or epilepsy
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Known or suspected pregnancy,Current or history of thrombosis (deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke),History of cerebrovascular accident,Current or history of breast cancer or other estrogen-sensitive neoplasia,Undiagnosed abnormal uterine bleeding,Active liver disease or impaired liver function,Hypersensitivity to any component of the product,Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) at age ≥35,Major surgery with prolonged immobilization
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food interactions are reported for GILDESS 1/20. However, grapefruit juice may increase estrogen levels; advise patients to consume grapefruit products in moderation. Alcohol may impair judgment regarding missed doses; recommend moderate intake.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
GILDESS 1/20 (ethinyl estradiol 20 mcg/desogestrel 0.15 mg) is category X in pregnancy. First trimester: increased risk of congenital anomalies (e.g., heart defects, limb reduction) from estrogen component; cardiovascular and nervous system malformations reported. Second and third trimesters: associated with masculinization of female fetus from progestin; increased risk of IUGR and preterm birth. Use contraindicated in pregnancy.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in breast milk; ethinyl estradiol M/P ratio ~0.4, desogestrel M/P ratio ~0.6. May reduce milk quantity and quality; small amounts pose theoretical risk of estrogenic effects in infant. Generally not recommended during breastfeeding; alternative contraception advised.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustments applicable as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased hepatic metabolism, increased renal clearance) would reduce efficacy, but use is not recommended.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
GILDESS 1/20 is a monophasic oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate. It is indicated for contraception and may be used for acne vulgaris in women at least 15 years old. Monitor for breakthrough bleeding, especially in the first cycles. Counsel patients to take at the same time daily to maintain efficacy. Caution in women with migraine with aura, hypertension, or history of thromboembolism. Prescribe as a 21-day regimen with a 7-day hormone-free interval.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill at the same time every day, even if you do not have sex often.,If you miss a pill, follow the instructions in the package insert or consult your healthcare provider.,Use a backup method (like condoms) if you miss more than one pill or start late.,Common side effects include nausea, breast tenderness, and spotting, especially in the first few cycles.,Contact your doctor if you experience severe abdominal pain, chest pain, headache, vision changes, or leg pain/swelling.,Smoking increases the risk of serious cardiovascular side effects; avoid smoking while on this medication.,Do not take GILDESS if you are pregnant or suspect pregnancy.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GILDESS 1/20 vs ALYACEN 777, answered by our medical review team.
GILDESS 1/20 is a Oral Contraceptive that works by GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (Gn RH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GILDESS 1/20 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GILDESS 1/20 is: One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GILDESS 1/20 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GILDESS 1/20 is classified as Category C. GILDESS 1/20 (ethinyl estradiol 20 mcg/desogestrel 0.15 mg) is category X in pregnancy. First trimester: increased risk of congenital anomalies (e.g., heart defects, limb reduction. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.